Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib was effective in treating both early and late onset alopecia areata.

Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Axitinib treatment turned a man's grey hair back to black.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

The rash resolved after stopping ponatinib.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.

Ruxolitinib can help regrow hair in severe alopecia areata.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.

Upadacitinib improved multiple immune-related conditions in one patient.

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

JAK inhibitors show promise for treating various skin disorders effectively and safely.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.